Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States.
Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States.
复制标题
DOI：
10.1186/1471-2415-9-13
复制
发表时间：
2009-11-25
影响因子：
2
通讯作者：
Waycaster C
中科院分区：
文献类型：
--
作者：
Smith AF;Waycaster C
这项研究的目的是估计在美国治疗细菌性结膜炎(BC)的直接和间接年度成本。这是从美国医疗保健支付者的角度进行的疾病成本研究。对医学文献的全面审查补充了关于BC年发病率的数据，该数据来自于对2005年全国非卧床医疗保健调查(NAMCS)数据库的分析。就诊和实验室或诊断测试的成本估计是根据公布的Medicare CPT费用代码得出的。处方药成本从标准参考来源获得。间接成本被计算为因丧失生产力而产生的成本。由于BC的急性性质，没有进行成本贴现。所有成本均以2007美元表示。据估计，2005年美国的BC病例数量约为400万例，年发病率估计为每万人中有135例。基本病例分析估计，美国治疗BC患者的直接和间接总成本为5.89亿美元。单向敏感性分析，假设每年BC发病率或治疗费用变化20%，产生的成本范围为4.69亿至7.05亿美元。双向敏感性分析，假设每年BC发病率和治疗费用同时发生20%的变化，得出的估计成本范围为3.77亿至8.57亿美元。不列颠哥伦比亚省造成的经济负担很大。这些发现可能对决策者在分配必要的医疗资源以解决美国卑诗省的经济负担方面有用。
The aim of this study was to estimate both the direct and indirect annual costs of treating bacterial conjunctivitis (BC) in the United States. This was a cost of illness study performed from a U.S. healthcare payer perspective. A comprehensive review of the medical literature was supplemented by data on the annual incidence of BC which was obtained from an analysis of the National Ambulatory Medical Care Survey (NAMCS) database for the year 2005. Cost estimates for medical visits and laboratory or diagnostic tests were derived from published Medicare CPT fee codes. The cost of prescription drugs was obtained from standard reference sources. Indirect costs were calculated as those due to lost productivity. Due to the acute nature of BC, no cost discounting was performed. All costs are expressed in 2007 U.S. dollars. The number of BC cases in the U.S. for 2005 was estimated at approximately 4 million yielding an estimated annual incidence rate of 135 per 10,000. Base-case analysis estimated the total direct and indirect cost of treating patients with BC in the United States at $ 589 million. One- way sensitivity analysis, assuming either a 20% variation in the annual incidence of BC or treatment costs, generated a cost range of $ 469 million to $ 705 million. Two-way sensitivity analysis, assuming a 20% variation in both the annual incidence of BC and treatment costs occurring simultaneously, resulted in an estimated cost range of $ 377 million to $ 857 million. The economic burden posed by BC is significant. The findings may prove useful to decision makers regarding the allocation of healthcare resources necessary to address the economic burden of BC in the United States.
登录
查看更多内容
影响因子：
2.2
作者：
Everitt, H;Little, P
通讯作者：
Little, P
影响因子：
--
作者：
DART, JKG
通讯作者：
DART, JKG
DOI：
10.1007/s00417-007-0573-x
发表时间：
2008-01-01
影响因子：
2.7
作者：
Happich, Michael;Reitberger, Ursula;Watkins, Jessamy
通讯作者：
Watkins, Jessamy
影响因子：
4.5
作者：
Chaberny, IF;Schnitzler, P;Wendt, C
通讯作者：
Wendt, C
影响因子：
11.5
作者：
Donahue, SP;Khoury, JM;Kowalski, RP
通讯作者：
Kowalski, RP